Skip to content
‹ Back to IndustriesSciences

Listen: Biotech Firms Set Their Funding Sights High

Several biotech firms are aiming to secure significant funding in the new year, following a period of financial uncertainty. ARMO BioSciences, Solid, and resTORbio are among the companies seeking approximately $271 million for research and development. These companies focus on innovative therapies like immunotherapy and gene-transfer therapy for treating serious diseases.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · · Promoted Content
Share
Listen: Biotech Firms Set Their Funding Sights High

Key takeaways

01

Biotech companies plan to raise $271 million for research and development.

02

Companies like ARMO BioSciences and Solid are focusing on innovative therapies.

03

The biotech sector is rebounding after a challenging financial period in 2016 and early 2017.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

The arrival of the new year also brings with it, the arrival of new products in the marketplace. Of specific interest this year are several biotech firms that have their funding sights set fairly high. While 2016 and the 1st quarter of 2017 were somewhat bleak for the industry financially speaking, there was a definite uptick beginning in the 2nd quarter of 2017. The Redwood City, California firm, ARMO BioSciences is gathering funding for its white-blood cell boosting immunotherapy offering. On the other coast, Cambridge, Massachusetts-based laboratory, Solid, is moving forward with its gene-transfer therapy aimed at Duchenne Muscular Dystrophy. Finally, anti-aging research continues right down the road at resTORbio, in Boston. These 3 biotech companies are aiming to acquire approximately $271 million in capital this year to continue their research and development.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Peptide drug runs can stall on late raw materials, Frost & Sullivan and Medtide find

Peptide drug runs can stall on late raw materials, Frost & Sullivan and Medtide find

Frost & Sullivan and Medtide's 2026 white paper on peptide and oligonucleotide drugs ties contract manufacturer selection to program stage. Its sharpest point is that a late resin, amino acid or nucleotide building block can stall a campaign even with plant capacity free. Supplier depth belongs in CDMO qualification.

  • 01Open capacity at a contract manufacturer means little if a nonstandard amino acid or a modified nucleotide building block arrives late, so the supplier list deserves the same scrutiny as the capacity reservation.
  • 02What makes a good CDMO changes as a program matures: speed of problem solving decides early clinical timelines, while proven scale-up, raw-material access, reserved capacity and site-to-site transfer decide launch readiness.
  • 03A useful question for any prospective partner is which critical inputs for a given molecule already have a second qualified supplier, because switching sources later can trigger extra quality testing.

Nov 22, 2026

Merck's $550 million lab was built for robots whose specs weren't final

Merck's $550 million lab was built for robots whose specs weren't final

Merck's $550 million ADVANCE lab in West Point, Pennsylvania, which opened in October 2026, reserved floor space for robots before some of them had final dimensions. Containment sits inside robotic work cells, space and utilities were sized for the largest expected machines, and validation waited until construction ended. Other lab capital projects can reuse that order of work.

  • 01When robotic platforms carry their own enclosures, walls are needed mainly where the science or access control demands them, and the open floor plan is designed to make future equipment swaps easier without automatically forcing new room build-outs.
  • 02Merck planned for the largest expected robot sizes and highest utility needs, using lessons from its 2023 Spring House lab, according to Lab Design News. Teams without a previous project to learn from could find those limits harder to set.

Nov 21, 2026

Keller’s case for carbs as key fuel for post-workout muscle repair

Keller’s case for carbs as key fuel for post-workout muscle repair

In a NuLiv Science segment, nutrition scientist and dietitian Dr. Rosa Keller argues that carbohydrate (glucose) is a key fuel for mitochondrial ATP after resistance training and that clients often under-eat carbs. The article cites reviews emphasizing carbohydrate for glycogen restoration (including John Ivy’s 1.2 g/kg/hour post-exercise target), describes protein as a co-ingested partner in recovery, and notes ketogenic-diet findings that may benefit aging mitochondria.

  • 01John Ivy's post-exercise carbohydrate target is about 1.2 grams per kilogram of body weight per hour, taken early and often, to maximize glycogen resynthesis.
  • 02Nature Metabolism describes carbohydrate as the primary fuel for ATP in most Olympic events, and Keller argues that post-exercise repair depends on mitochondria having fuel to generate ATP.
  • 03Ketogenic diets improve muscle mitochondrial mass and function with age or disease but not in athletes, Pathak and Baar concluded, so the carbohydrate rule depends on who is training.

Nov 20, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512